Information Provided By:
Fly News Breaks for January 12, 2017
Jan 12, 2017 | 08:08 EDT
JMP Securities analyst David Turkaly says that Integra LifeSciences' (IART) acquisition of Derma Sciences (DSCI) "appears strategically favorable." He says that the deal enhances several of the company's key existing product lines while enabling it to expand its regenerative platform to amniotic technology and manufacturing. He reiterates a $50 price target and an Outperform rating on the stock.
News For IART;DSCI From the Last 2 Days
There are no results for your query IART;DSCI